Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Amendment Flag
Entity Voluntary Filers
Current Fiscal Year End Date
Entity Well Known Seasoned Issuer
Entity Small Business
Entity Shell Company
Entity Emerging Growth Company
Entity Current Reporting Status
Document Period End Date
Entity Filer Category
Document Fiscal Period Focus
Document Fiscal Year Focus
Entity Common Stock Shares Outstanding
Entity Public Float
CONSOLIDATED BALANCE SHEETS
Statement [Table]
Statement [Line Items]
Statement Class Of Stock Axis
Common Class A [Member]
Common Class B [Member]
Current Assets:
Cash
Prepaid expenses and other current assets
Security deposit
Total Current Assets
Other Assets:
Patent costs - net
Property, plant and equipment - net
Deferred offering costs
Security deposit
[Security Deposit]
Total Other Assets
Total Assets
Current Liabilities:
Accounts payable - (including related party payables of approx. $1,511,000 and $1,504,000, respectively)
Accrued expenses - (including related party accruals of approx. $45,000 and $58,000, respectively)
Accrued salaries and payroll taxes - (including related party accrued salaries of approx. $3,129,000 and $2,953,000, respectively)
Note payable - related party
Total Current Liabilities
Other Liabilities:
Series B 5% convertible preferred stock liability at $1,080 stated value; 1,196 and 0 shares issued and outstanding at June 30, 2019 and 2018, respectively
Total Liabilities
Commitments and contingencies (Note 8)
Stockholders' Deficiency
Preferred stock, $0.001 par value, 10,000,000 designated shares, no shares issued and outstanding
Additional paid-in capital
Accumulated deficit
Treasury Stock, at cost (228,218 shares and 0 shares as of June 30, 2019 and 2018, respectively)
Total Stockholders' Deficiency
[Stockholders' Equity Attributable to Parent]
Total Liabilities and Stockholders' Deficiency
[Liabilities and Equity]
Common Stock value
Current Liabilities
Related party payables
Related party expenses
Related party accrued salaries
Other Liabilities:
Convertible preferred stock liability, stated value
Convertible preferred stock, shares issued
Convertible preferred stock, shares outstanding
Stockholders' Deficiency
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Preferred stock, shares designated
Treasury Stock Shares
Common Stock, shares issued
Common Stock, shares outstanding
Common Stock, shares authorized
Common stock , par value
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues
Operating expenses:
Research and development expenses
General and administrative expenses
Officers' payroll and payroll tax expenses
Professional fees
Total operating expenses
Loss from operations
Other expenses
Interest income
Interest expense - debt
Interest expense - preferred stock
[Interest Expense]
Change in fair value of preferred stock
Modification of Series B preferred stock terms
Financing costs
Total other expenses
Loss before provision for income taxes
Provision for income taxes
Net loss
Basic and diluted loss per share attributable to common stockholders
Weighted average number of common shares
CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY
Equity Components [Axis]
Common Stock A [Member]
Common Stock B [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Treasury Stock [Member]
Balance, shares
[Shares, Issued]
Balance, amount
Shares sold to Aspire Capital under 2015 Agreement at $0.74 - $0.94 range, Shares
Net Income (Loss)
Shares sold to Aspire Capital under 2015 Agreement at $0.74 - $0.94 range, Amount
Shares sold to Aspire Capital under 2017 Agreement at $0.25 - $0.76 range,Shares
Shares sold to Aspire Capital under 2017 Agreement at $0.25 - $0.76 range, Amount
Shares sold to Aspire Capital under 2018 Agreement at a discounted purchase price of $0.29 per share, net, Shares
Shares sold to Aspire Capital under 2018 Agreement at a discounted purchase price of $0.29 per share, net, Amount
Shares issued as commitment fee, 9/6/2017 at $0.715, Shares
Shares issued as commitment fee, 9/6/2017 at $0.715, Amount
Shares and warrants issued as commitment fee, Shares
Shares and warrants issued as commitment fee, Amount
Offering cost
Shares issued to officer as equity awards at $0.705 - 1.40
Shares issued to employees for services at $0.705 - $1.37
Shares issued to consultant for services at $0.43, Shares
Shares issued to consultant for services at $0.43, Amount
Stock options issued to officer as equity awards at $1.39
Stock options issued to employees for services at $0.705 - $1.37
Stock options issued to consultant for services at $0.15 - $0.73
Issuance of vested shares to Officer and employees, Shares
Cancellation of all treasury shares, Shares
Cancellation of all treasury shares, Amount
Shares issued to officer as equity awards at $0.398 to $0.705
Shares issued to consultant for services at $0.84 - $1.38
Stock options issued to employee for services at $0.398 - $1.37
Stock options issued to consultant for services at $0.43 - $0.73
Issuance of vested shares to Officer, and Consultant, Shares
Shares issued to employee for services at $0.398 - $1.37
Stock options issued to officer as equity awards at $0.398 to $0.705
Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B, Shares
Issuance of shares for tax purposes as Treasury Shares, Shares
Conversion of preferred stocks to common stock, Shares
Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B, Amount
Allocating warrants (proportion of value exercised) to Pref Stock Liability
Issuance of shares for tax purposes as Treasury Shares, Amount
To record underlying Series 1, Series 2 and Series 3 Warrants attached to 2,000 shares Series B Preferred Stock
Reversal of the stock based compensation related to unvested options and shares for employee from 7.1.18-12.31.2018
To record beneficial conversion feature of Series B preferred stock & warrants discounts
Conversion of preferred stocks to common stock, Amount
To record issuance of 2,500 warrants Series B Preferred Stock per 5.9.2019 Modification
Dividend paid by issuance of preferred stock for Q2-12/31/18
Withholding and Purchase of 305,792 treasury shares from vested shares issued - at cost, shares
Withholding and Purchase of 305,792 treasury shares from vested shares issued - at cost, amount
Balance, shares
Balance, amount
CONSOLIDATED STATEMENTS OF CASH FLOWS
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock and stock options issued as employee compensation and payment for services
Amortization of patent costs Basic and diluted loss per share
Patent write off
Depreciation of equipment
(Gain) Loss on disposal of equipment
Interest expense-preferred stock
Deferred financing costs write off
Modification of Series B convertible preferred stock terms
Change in fair value of preferred stock
[Change in fair value of preferred stock]
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
[Increase (Decrease) in Prepaid Expense and Other Assets]
Accounts payable
Accrued expenses
Accrued officers' salaries and payroll taxes
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales proceeds of property, plant and equipment
Patent costs
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Sale of common stock, net of offering costs
Purchase of treasury stock
Proceeds from issuance of Series B Preferred stocks, net of financing costs
Proceeds from exercise of warrants
Net cash provided by financing activities
NET DECREASE IN CASH
CASH, BEGINNING OF YEAR
CASH, END OF YEAR
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW INVESTING AND FINANCING ACTIVITIES
Purchase of treasury stock offset by subscription receivable
Allocating warrants (proportion of value exercised) to preferred stock liability
Initial warrant valuation
Beneficial conversion features on preferred stock and warrant discounts
Issuance of 2,500 warrants for preferred stock modification
Stock dividend paid by issuance of preferred stock
Conversion of Series B Convertible Preferred stock to Common stock
Cancellation of shareholder debt for the purchase of 909,090 shares of Common Stock Class B shares
Basis of Presentation and Nature of Operations
Note 1. Basis of Presentation and Nature of Operations
Going Concern and Liquidity
Note 2. Going Concern and Liquidity
Note 3. Significant Accounting Policies and Recent Accounting Pronouncements
Patents, net
Note 4. Patents, net
Property, plant and equipment, net
Note 5. Property, plant and equipment, net
Accrued Expenses - Related Parties and Other
6. Accrued Expenses - Related Parties and Other
Accrued Salaries and Payroll Taxes - Related Parties And Other
Note 7. Accrued Salaries and Payroll Taxes - Related Parties And Other
Commitments and Contingencies
Note 8. Commitments and Contingencies
Related Party Transactions
Note 9. Related Party Transactions
Convertible Note Payable - Related Party
Note 10. Convertible Note Payable - Related Party
Weighted Average Shares Outstanding
Note 11. Weighted Average Shares Outstanding
Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding
Note 12 - Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding
Equity Transactions
Note 13. Equity Transactions
Series B 5 convertible preferred stock
Note 14 - Series B 5% convertible preferred stock
Fair Value Measurement
Note 15 - Fair Value Measurement
Income Taxes
Note 16 - Income Taxes
Subsequent Events
Note 17 - Subsequent Events
Use of Estimates
Cash
Cash and Cash Equivalents, Policy [Policy Text Block]
Equipment
Intangible Assets - Patents
Financial Instruments
Certain Risks and Uncertainties
Concentrations of Credit Risk
Accrued Outsourcing Costs
Valuation of Equity Grants
Income Taxes
Income Tax, Policy [Policy Text Block]
Basic Loss per Share
Treasury Stock
Accounting for Stock Based Compensation
Recent Adopted Accounting Pronouncements
Recently Issued Accounting Guidance
Equipment
[Equipment]
Schedule of components of stock based compensation related to stock options recognized in the company's statement of operations
Patents, net (Tables)
Schedule of patents
Property, plant and equipment, net (Tables)
Property, plant and equipment
Accrued Expenses Related Parties and Other (Tables)
Schedule of accrued expenses
Accrued Salaries and Payroll Taxes Related Parties And Other (Tables)
Schedule of accrued salaries and payroll taxes
Commitments and Contingencies (Tables)
Future minimum lease payments required under the non-cancelable operating lease
Weighted Average Shares Outstanding (Tables)
Weighted Average Shares Outstanding
Schedule of Weighted Average Number of Shares [Table Text Block]
Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Tables)
Award Type Axis
Derivative Instrument [Axis]
Stock Options [Member]
Warrant [Member]
Schedule of Restricted Stock Award Activity
Schedule of vesting outstanding restricted stock
Schedule of stock options/warrants activity
Valuation assumptions for stock options/warrants and SARs
Schedule of outstanding common stock warrants
Series B 5 convertible preferred stock (Tables)
Schedule of fair value of the Series B convertible preferred stock
Fair Value Measurement (Tables)
Schedule of renconciliation of the company
Income Taxes (Tables)
Federal and State statutory income tax rate
Components of deferred tax assets
Basis of Presentation and Nature of Operations (Details Narrative)
State of incorporation
Date of incorporation
Going Concern and Liquidity (Details Narrative)
Plan Name [Axis]
Related Party [Axis]
Title of Individual [Axis]
Issuance Agreement [Member]
Securities Purchase Agreement [Member]
Investor [Member]
Director [Member]
Going Concern [Member]
Accumulated deficit
Total budgeted expenditures
Cash
Total Current Liabilities
Due to related parties
Net cash used in operating activities
Net loss
Working capital (deficit)
Proceeds from exercise of warrants
Warrants received
Convertible preferred stock, shares outstanding
Cash and cash equivalent
Preferred stock, shares outstanding (in shares)
Agreement description
Preferred stock issued, shares
Preferred stock purchased
Preferred stock value
Convertible preferred stock, shares
Warrants issued, shares
Warrant issued, value
Significant Accounting Policies and Recent Accounting Pronouncements (Details)
Equipment
[Property, Plant and Equipment, Useful Life]
Income Statement Location Axis
Research and Development Expense [Member]
Professional fees
Employees' bonus
Officers' bonus
Total stock-based compensation expense
Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)
Finite Lived Intangible Assets By Major Class Axis
Range Axis
Indefinite Lived Intangible Assets By Major Class Axis
Patents [Member]
Minimum [Member]
Maximum [Member]
IntangibleAssets [Member]
Patent costs - net
[Finite-Lived Intangible Assets, Net]
Amortization expense of patent costs
Adjustment to general and administrative expenses, patent
Patent write off
Research and development expenses
FDIC insured limit above amount
Treasury Stock value
Treasury Stock, at cost (0 shares and 262,080 shares as of June 30, 2018 and 2017, respectively)
Intangible assets amortization period
Patents, net (Details)
Patents Two [Member]
Patents Three [Member]
Patents [Member]
Purchased Patent Rights
Patent costs - net
Useful life
Accumulated amortization
Patents, net (Details Narrative)
Year 2020 - 2025 [Member]
Year 2026 [Member]
Amortization expense
Patent write off
Estimated remaining useful lives of the assets
Future amortization period
Estimated annual amortization expense
Property, plant and equipment, net (Details)
Testing equipment
Less: Accumulated depreciation
[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]
Property, plant and equipment - net
Property, plant and equipment, net (Details Narrative)
Depreciation expense
Accrued Expenses - Related Parties and Other (Details)
Accrued research and development consulting fees
Accrued rent (Note 9) - related parties
Accrued interest (Note 10) - related parties
Total
Accrued Salaries and Payroll Taxes - Related Parties And Other (Details)
Accrued salaries - related parties
Accrued payroll taxes - related parties
Accrued employee bonuses
Withholding tax - payroll
Total
[Employee-related Liabilities, Current]
Commitments and Contingencies (Details)
Year ending June 30,
2020
2021
2022
2023
Thereafter
Total minimum payments
Commitments and Contingencies (Details Narrative)
Operating leases, rental expense
Lease term
Lease expiry date
Rent expense (monthly)
Total contractual commitments
Related Party Transactions (Details Narrative)
Kard Scientific [Member]
Clinical Studies [Member]
Rent expense
Accrued research and development expenses
Convertible Note Payable Related Party (Details Narrative)
Related Party Transaction Axis
Ehrlich Promissory Note C [Member]
Mr. Ehrlich [Member]
Ehrlich Promissory Notes A and B [Member]
Minimum [Member]
Maximum [Member]
Common Class B
Leo Ehrlich [Member]
Accrued interest - related parties
Principal balance of demand notes
Total outstanding balance of principal and interest
Interest rate
Common stock price per share
Equity incentive shares
Exercise price
Closing bid price per share
Percentage of closing bid price
Additional loan amount
Amount of debt extinguished
Common stock shares issued upon extinguishment of debt
Weighted Average Shares Outstanding (Details)
Weighted average shares outstanding-basic
Dilutive options and restricted stock and warrants
Weighted average shares outstanding-diluted
Antidilutive securities not included:
Stock options
Stock options arising from convertible note payable and interests
Restricted stock grants
Warrants
Convertible preferred stock
Total
[Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount]
Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details)
Stock options [Member]
Number of Options
Number of Outstanding, Beginning Balance
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]
Granted
Exercised
Forfeited/expired
Number of Outstanding, Ending Balance
Number of Options Exercisable, Ending Balance
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number]
Unvested stock options
[Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested]
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]
Granted
[Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price]
Exercised
[Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]
Forfeited/expired
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price]
Weighted Average Exercise Price, Ending Balance
Weighted Average Exercise Price, Exercisable
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price]
Unvested stock options
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life (Years), Outstanding, Beginning Balance
Granted
[Granted]
Weighted average remaining contractual life (Years), Outstanding, Ending Balance
Weighted average remaining contractual life (Years), Exercisable
Weighted average remaining contractual life (Years), Unvested stock options
Aggregate Intrinsic Value
Aggregate intrinsic value, Beginning Balance
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value]
Aggregate intrinsic value, Ending Balance
Aggregate intrinsic value, Exercisable
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value]
Aggregate intrinsic value, Unvested stock options
Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 1)
Expected term (in years)
Expected stock price volatility
[Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum]
Risk-free interest rate
[Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum]
Expected stock price volatility
Risk-free interest rate
Expected dividend yield
Restricted Stock [Member]
Total shares granted
Total shares vested
Total shares forfeited
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period]
Total shares granted
[Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value]
Total shares vested
[Total shares vested]
Total shares forfeited
[Total shares forfeited]
Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 3)
Scheduled vesting
Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details 4)
Series B preferred stock warrants [Member]
Granted
Exercised
Expired
Weighted Average Exercise Price
Granted
Exercised
Expired
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life (Years), Outstanding, Beginning Balance
Granted
Exercised
[Exercised]
Weighted average remaining contractual life (Years), Outstanding, Ending Balance
Aggregate Intrinsic Value
Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 5)
Expected term (in years)
[Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term]
Expected stock price volatility
[Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate]
Risk-free interest rate
[Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate]
Expected dividend yield
Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details 6)
Common Stock Warrants [Member]
Extended
Granted
Exercised
[Exercised 1]
Expired
Weighted Average Exercise Price
Extended
[Extended]
Weighted Average Remaining Contractual Life (Years)
Granted
[Granted 1]
Weighted average remaining contractual life (Years), Outstanding, Ending Balance
Aggregate Intrinsic Value
Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details Narrative)
Award Date Axis
Employee Stock Ownership Plan (ESOP) Name [Axis]
Legal Entity Axis
Warrant [Member]
Mr. Ehrlich [Member]
Stock options [Member]
On September 1, 2018 [Member]
Dr. Arthur Bertolino [Member]
On September 1, 2018 [Member]
[On September 1, 2018 [Member]]
Ms. Jane Harness [Member]
2016 Equity Incentive Plan [Member]
On June 30, 2016 [Member]
Consultant 1 [Member]
Dr. Bertolino [Member]
On September 1, 2019 [Member]
Series B [Member]
On May 29, 2018 [Member]
Dr. Krishna Menon [Member]
Employees [Member]
Ms. Harness [Member]
On June 28, 2018 [Member]
Ms. Anne Ponugoti [Member]
On September 1, 2017 [Member]
Securities Purchase Agreement [Member]
[Securities Purchase Agreement [Member]]
Aspire Capital Fund LLC [Member]
Series 1-2 warrants [Member]
Series 1-3 warrants [Member]
Additional Three year [Member]
June 1, 2018 [Member
Securities Purchase Agreement [Member]
Series 1 warrant [Member]
Series 2 warrant [Member]
Series 3 warrant [Member]
December 1, 2018 [Member]
June 1, 2019 [Member]
December 1, 2019 [Member]
On February 1, 2018 [Member]
Consultant [Member]
On February 10, 2018 [Member]
Two Consultant [Member]
Series 4 warrant [Member]
Share based compensation
Restricted stock awards
Treasury stock outstanding
Total cumulative cost
Unrecognized compensation cost related to unvested restricted stock-based compensation
Compensation cost not yet recognized, period for recognition
Expected share based compensation expenses
Stock options to purchase shares, value
Shares award expense
Options vested or expected to vest
Preferred stock, shares outstanding (in shares)
[Preferred stock, shares outstanding (in shares)]
Stock option expenses
Purchase of warrants
Number of warrants exercised
Proceeds from warrant exercises
Stock issued during period, shares
Exercisable period
Stock option vested or to be vested, description
Stock options reserved for future issuance
Stock option exercise price
Stock issued, shares
Stock issued, value
Restricted stock shares issued
Taxable share based compensation
Closing stock price
[Closing stock price]
Common stock shares issued
Remaining common stock shares withheld
Vesting percentage
Vested shares
Rights and preferences of preferred stock description
Proceeds from issuance of shares
Additional shares of preferred stock
Preferred stock shares issued
Stock awards
Restricted stock
Stock option vested or to be vested, description
[Stock option vested or to be vested, description]
Number of installments
Stock options granted value
Stock option Granted
Exercise price
Stock options value reserved for future issuance
Exercise price
[Exercise price]
Warrants exercisable period
Closing stock price
Remaining common stock shares withheld
[Remaining common stock shares withheld]
Vested shares
[Vested shares]
Beginning balance, Shares
Proceeds from issuance of warrants
Common stock shares issuable under agreement
Exercised
Preferred stock shares reserved for future issuance
Equity Transactions (Details Narrative)
Stock And Warrant [Member]
Aspire Capital Fund LLC [Member]
Common Class A
30 Million Common Stock Purchase Agreement [Member]
New 30 Million Common Stock Purchase Agreement [Member]
Treasury stock outstanding
[Weighted Average Number of Shares, Treasury Stock]
Deferred offering costs
Common stock shares issued upon extinguishment of debt
Amount of debt extinguished
Exercise price
[Share Price]
Common stock shares issued
Commitment fee recorded to additional paid in capital
Common stock shares reserve for future issuance
Common Stock, par value (in dollars per share)
Common Stock, shares outstanding (in shares)
Term of the purchase agreement
Common stock shares sold
Proceeds from issuance of common stock
Value of common stock shares issuable under agreement
Amortization of commitment fee, Amount amortized
Description for satisfaction of trading price condition
Allocation of commitment fee description
Series B 5 convertible preferred stock (Details)
Expected dividend yield
[Expected dividend yield]
Expected stock-price volatility
Risk-free interest rate
[Risk-free interest rate]
Expected term of warrants (years)
Stock price
Exercise price
[Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price]
Series B 5 convertible preferred stock (Details Narrative)
On September 1, 2018 [Member]
Ms. Jane Harness [Member]
Series B [Member]
Series B Preferred Stock [Member]
Proceeds from issuance of shares
Proceeds from warrant exercises
[Proceeds from warrant exercises]
Conversion of preferred stock to common stock description
Conversion of Series B Convertible Preferred stock to Common stock, reversed
Amount of series B preferred stock dividends paid
5% accrued dividend
5% accrued dividend
[5% accrued dividend]
Beginning balance, Shares
Stock issued description
Warrants to purchase additional shares
Rights and preferences of the preferred stock description
Conversion cap limits description
Number of warrants exercised
[Number of warrants exercised]
Stock issued during period, shares
Stock issued during period, value
Beneficial conversion feature
Stock issuance cost
Preferred stock, shares outstanding (in shares)
Change in fair value of preferred stock liabilities
Loss due to change in fair value of preferred stock
Warrants exercised description
Terms of agreement
Purchase of warrants
Fair Value Measurement (Details)
Balance, beginning of year
[Balance, beginning of year]
Issuance of preferred stock at fair value
Issuance of preferred stock by exercise of 1,275 warrants
Conversion of preferred stock to common stock
Contingent consideration
Change in fair value of preferred stock due to modification of terms
Issuance of 100 shares valued at $535.12 per share Series B Preferred Stock per May 2019 Modification
5% accrued dividend (1)
Balance, end of year
Fair Value Measurement (Details Narrative)
Dividends recorded as interest expense
Amount of series B preferred stock dividends paid
5% accrued dividend
Income Taxes (Details)
Book income at federal statutory rate
State income tax, net of federal tax benefit
Change in valuation allowance
Research and development credit
Permanent difference
Change in Federal Statutory Rate
Others - net
Total
[Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent]
Income Taxes (Details 1)
Deferred tax asset:
Net operating loss carry forwards
Accrued payroll
Stock compensation
Research and development credit
[Research and development credit]
Other
Deferred tax assets, Total
Valuation allowance
Total deferred taxes
Income Taxes (Details Narrative)
Operating loss carryforward
Description for the ability to carryforward losses
Subsequent Events (Details Narrative)
2016 Equity Incentive Plan [Member]
Preferred Stock Warrants [Member]
Common Stock Class A
Preferred stock shares issued upon exercise of warrants
Preferred stock shares converted
Common stock shares issued upon conversion of preferred stock
Common stock shares issued for services
Stock options issued
Value of stock options issued
Exercise price of stock options
Term of stock options
Description for vesting of shares
Common Stock, shares authorized
Payment due following commencement of first phase 3 clinical trial of Brilacidin
Payment due upon filing of a marketing approval application
Additional payments payable upon achievement of certain milestones under agreement by related party